Stockscreener 앱 받기
33.54
1.45%
0.48
시간 외 거래:
33.54
전일 마감가:
$33.06
열려 있는:
$32.65
하루 거래량:
1.40M
Relative Volume:
0.85
시가총액:
$3.20B
수익:
$305.00K
순이익/손실:
$-328.98M
주가수익비율:
-7.8636
EPS:
-4.2652
순현금흐름:
$-309.60M
1주 성능:
+2.76%
1개월 성능:
+5.21%
6개월 성능:
+94.10%
1년 성능:
+77.37%
1일 변동 폭
$32.61
$33.65
1주일 범위
$31.26
$33.65
52주 변동 폭
$9.90
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
명칭
Viridian Therapeutics Inc
전화
617.272.4600
주소
221 CRESCENT STREET, WALTHAM
VRDN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
33.54 | 3.16B | 305.00K | -328.98M | -309.60M | -4.2652 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 재확인 | Wedbush | Outperform |
| 2025-12-03 | 개시 | William Blair | Outperform |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-08-25 | 재개 | Jefferies | Buy |
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 개시 | TD Cowen | Buy |
| 2024-09-11 | 재확인 | Needham | Buy |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-05-09 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | 개시 | BTIG Research | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-05-30 | 개시 | RBC Capital Mkts | Outperform |
| 2023-04-17 | 개시 | Wells Fargo | Overweight |
| 2023-03-30 | 개시 | Stifel | Buy |
| 2022-12-19 | 개시 | Cowen | Outperform |
| 2022-12-19 | 개시 | Needham | Buy |
| 2022-12-16 | 개시 | Credit Suisse | Outperform |
| 2022-12-01 | 개시 | H.C. Wainwright | Buy |
| 2022-06-23 | 개시 | B. Riley Securities | Buy |
| 2021-11-18 | 개시 | SVB Leerink | Outperform |
| 2021-10-12 | 개시 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) - Seeking Alpha
(VRDN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pullback Watch: What are Viridian Therapeutics Incs earnings expectationsJuly 2025 Update & Expert-Curated Trade Recommendations - baoquankhu1.vn
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $44 - 富途资讯
Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) Business Is Trailing The Industry But Its Shares Aren't - 富途资讯
Did FDA Priority Review and EU Push for Thyroid Eye Drug Just Shift Viridian Therapeutics' (VRDN) Investment Narrative? - Sahm
SG Americas Securities LLC Acquires 49,981 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics stock hits 52-week high at $34.06 By Investing.com - Investing.com Nigeria
Responsive Playbooks and the VRDN Inflection - Stock Traders Daily
Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline - TechStock²
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 52-Week HighStill a Buy? - MarketBeat
Viridian Therapeutics stock hits 52-week high at $34.06 - Investing.com
Market Review: Is Viridian Therapeutics Inc stock a good pick for beginnersPortfolio Return Report & Capital Efficiency Focused Ideas - baoquankhu1.vn
Viridian Therapeutics, Inc. (VRDN): Growth Potential in Biotechnology with an 81,958% Revenue Surge - DirectorsTalk Interviews
Will Viridian Therapeutics Inc. stock continue upward momentumJuly 2025 Decliners & Real-Time Buy Zone Alerts - Улправда
Viridian Therapeutics (NASDAQ:VRDN) Upgraded by UBS Group to "Strong-Buy" Rating - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2026 - BioSpace
Assessing Viridian Therapeutics (VRDN) Valuation After FDA Priority Review For Veligrotug - Sahm
What MACD trends signal for Viridian Therapeutics Inc. (1S1) stockPortfolio Performance Report & Expert Curated Trade Setup Alerts - ulpravda.ru
Will Viridian Therapeutics Inc. stock continue dividend increasesJuly 2025 Short Interest & Low Drawdown Trading Techniques - ulpravda.ru
Is Viridian Therapeutics Inc. stock attractive after correctionCPI Data & Technical Entry and Exit Alerts - Улправда
How Viridian Therapeutics Inc. stock compares to market leaders2025 Trading Volume Trends & Expert Approved Momentum Ideas - Улправда
Viridian Therapeutics, Inc.Common Stock (NQ: VRDN - FinancialContent
Why CHRO stock attracts strong analyst attention - Улправда
Can Viridian Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Market Review & Real-Time Chart Pattern Alerts - Улправда
VRDN: Truist Securities Lowers Price Target but Maintains Buy Ra - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $40.00 at Truist Financial - MarketBeat
Why Viridian Therapeutics Inc. stock is in analyst buy zonePortfolio Gains Report & Smart Investment Allocation Insights - Улправда
UBS Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛
Oklahoma City NewsThe Oklahoman - FinancialContent
UBS Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq
Will Viridian Therapeutics Inc. stock deliver consistent dividendsLong-Term Growth Stocks & Turn Market Volatility into Wealth - Улправда
VRDN: UBS Initiates Coverage with a 'Buy' Rating and $50 Price T - GuruFocus
Why Viridian Therapeutics Inc. stock remains resilientHigh Beta Stocks & Outstanding Portfolio Tips - Улправда
Free cash flow per share of Viridian Therapeutics, Inc. – DUS:1S1 - TradingView — Track All Markets
UBS initiates Viridian Therapeutic stock with Buy rating on TED treatment - Investing.com Canada
Jefferies reiterates Buy rating on Viridian Therapeutic stock with $44 target - Investing.com Canada
Viridian Therapeutic stock a Top Pick at TD Cowen ahead of busy 2026 - Investing.com Canada
Viridian Therapeutics Prepares for Transformational 2026 - BioSpace
Viridian Therapeutics, Inc. (VRDN) Investor Outlook: Exploring a Potential 36.59% Upside in the Biotech Arena - DirectorsTalk Interviews
About Us | Laser Focus WorldViridian Therapeutics Prepares for Transformational 2026 - FinancialContent
Entry Recap: Will Viridian Therapeutics Inc. stock outperform international peersMarket Volume Report & Consistent Profit Trading Strategies - ulpravda.ru
Is Viridian Therapeutics Inc. stock positioned for long term growth2026 world cup usa national team qualification midfield engines high defensive line tactical prediction insights - ulpravda.ru
Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial - MSN
VRDN Stock Price, Forecast & Analysis | VIRIDIAN THERAPEUTICS INC (NASDAQ:VRDN) - Chartmill
What to keep an eye on in 2026 - Eyes On Eyecare
Understanding the Setup: (VRDN) and Scalable Risk - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock - MarketBeat
Insider Sell: Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics Inc (VRDN) - GuruFocus
Viridian Therapeutics (VRDN) Chief Legal Officer reports 2,272-share stock sale - Stock Titan
Viridian Therapeutics Inc (VRDN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):